In the specification:

On page 18, please replace the paragraph beginning at line 10 with the following rewritten paragraph:

- - In certain embodiments, the invention provides a method for inducing an immune response against an antigen that does not elicit an effective host immune response, the method comprising administering to the host a lose-low dose or a small amount of a binding agent that binds an epitope of a soluble form of the antigen. In certain embodiments the invention provides for a method for inducing an immune response against an antigen that does not elicit an effective host immune response, the method comprising administering to the host a binding agent that binds an epitope of a soluble form of the antigen using a low dose of binding agent, preferably a dose that does not produce ADCC and/or induce antibody-mediated toxicity. In some embodiments of the invention, low dose of binding agent comprises from about 0.1 µg to about 2 mg per kg of body weight of the host. In some embodiments of the invention, the antigen is a cellular antigen. ADCC is assessed by incubating ⁵¹CR-labeled tumor cells with a binding agent according to the invention and adding fresh human PBMCs, followed by incubation for four hours and measurement of specific lysis. ADCC is deemed to be absent if specific lysis is less than 15%. As used herein, antibody-mediated toxicity refers to clinical toxicity, specific indicators of which include, but are not limited to, abnormal serum chemistries, impaired renal function, and signs and symptoms of serum sickness or anaphylaxis. - -